

Published in final edited form as:

J Am Chem Soc. 2007 October 31; 129(43): 12926–12927. doi:10.1021/ja075881p.

## Trisubstituted Isoalloxazines as a New Class of G-Quadruplex Binding Ligands: Small Molecule Regulation of c-kit Oncogene Expression

Mallesham Bejugam, Sven Sewitz, Pravin S. Shirude, Raphaël Rodriguez, Ramla Shahid, and Shankar Balasubramanian\*

The University Chemical Laboratory, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, U.K.

Particular guanine rich DNA sequences can fold into stable four-stranded G-quadruplex structures, under physiological concentrations of Na<sup>+</sup> and K<sup>+</sup>, *in vitro*.<sup>1</sup> Such sequence motifs are found in the telomeres where they can fold into quadruplexes under the control of specific telomere binding proteins.<sup>2</sup> G-quadruplex motifs have been identified throughout the genome<sup>3</sup> and concentrate immediately upstream of transcription initiation sites.<sup>3a</sup> A number of these so-called “promoter quadruplex” sequences have been studied for several proto-oncogenes, including c-MYC,<sup>4</sup> BCL2,<sup>5</sup> VEGF,<sup>6</sup> KRAS<sup>7</sup> and two G-quadruplexes in the c-kit promoter<sup>8</sup> (c-kit1 and c-kit2). One working hypothesis couples quadruplex formation in promoters to transcription, suggesting an opportunity for chemical intervention of gene expression using small molecule G-quadruplex ligands. Some proof-of-concept has been provided for the case of c-MYC where small molecule ligands, TmPyP4,<sup>4</sup> and quindoline<sup>9</sup> derivatives have been shown to inhibit gene expression, while KRAS gene expression was inhibited by TmPyP4.<sup>7</sup>

The c-kit proto-oncogene encodes a tyrosine kinase receptor for the growth-promoting cytokine SCF (stem cell factor) which plays an important biological role in the control of differentiation.<sup>10</sup> A small molecule inhibitor of c-kit, Gleevec (imatinib mesylate), is being effectively used in the treatment of gastrointestinal stromal tumors (GIST).<sup>11</sup> A small molecule that inhibits c-kit expression at the transcriptional level would provide further evidence to support the promoter-quadruplex hypothesis and might inspire the exploration of quadruplex-based therapeutic approaches to address GIST. Herein, we report the design, synthesis, biophysical evaluation with primary biological data on 3,8,10-trisubstituted isoalloxazines (Figure 1).

The design of isoalloxazines as potential G-quadruplex ligands was inspired by the observation, arising from SELEX studies, that oxidized riboflavin (7,8-dimethyl-10-ribityl-isoalloxazine) binds to an intramolecular G-quartet with moderate binding affinity ( $K_d$ ) of 1–5  $\mu$ M.<sup>12</sup> Our design principles maintain the planar isoalloxazine scaffold, to enable interactions with G-quartet.<sup>13</sup> Amine side chains were introduced to provide potential for interactions with quadruplex loops and grooves and the negatively charged sugar–phosphate backbone.

© 2007 American Chemical Society

E-mail: sb10031@cam.ac.uk.

**Supporting Information Available:** Experimental procedures for the synthesis of isoalloxazines 1, SPR binding curves, experimental details, curves of FRET-melting and experimental procedures of cell based experiments. This material is available free of charge via the Internet at <http://pubs.acs.org>.

We developed and employed a short and robust synthetic route to 3,8,10-trisubstituted isoalloxazines to prepare ligands of general structure **1** (Figure 1). The key isoalloxazine building blocks were synthesized using modified literature procedures.<sup>14</sup> An efficient method was developed for the introduction of amino alkyl side chains to afford **1a–f** in good overall yields (see Supporting Information).

To evaluate the interaction properties of isoalloxazines **1a–f** with a number of DNA targets, we employed surface plasmon resonance (SPR) to evaluate equilibrium binding<sup>15</sup> and a fluorescence resonance energy transfer (FRET) melting assay<sup>16</sup> to evaluate the stabilizing influence of the ligand. We included three distinct G-quadruplex forming sequences in the study, the human telomeric DNA quadruplex sequence htelo [d(AGGG (TTAGGG)<sub>3</sub>)] and the two c-kit promoter G-quadruplex sequences c-kit18b [d(AGGGAGGGCGCTGGGAGGAGGG)] and c-kit28a [d(CGGGCGGGCGCGAGGGAGGGG)]. We have also included a duplex DNA [d(GGCATAGTGCGTGGGCGTTAGC)] hybridized with its complementary strand as a control. The SPR results (Table 1) revealed that ligands **1a–f**, bind to the various G-quadruplex DNA targets with measurable dissociation constants ranging from 3 to 69  $\mu\text{M}$ . None of the ligands showed significant binding to the control duplex.<sup>17</sup> All ligands tested showed a preference for binding to the c-kit2 quadruplex, with 3-fold selectivity for c-kit2 over c-kit1 for ligand **1d** and 14-fold selectivity for c-kit2 over htelo for ligand **1a** (Table 1). The discrimination between quadruplex DNA and duplex DNA has now been reported for a number of small molecule ligands, but the discrimination *between* distinct quadruplexes by a small molecule is perceived to be a greater challenge. Our observations support the potential for small molecules to discriminate between quadruplexes. We do not yet have structural information on the interaction of ligands **1a–f**, but we envisage that the observed quadruplex discrimination must, in some part, arise from the distinct loop topology and/or sequences exhibited for the quadruplexes under study.

The FRET-melting data (Table 1) showed that, with the exception of **1c**, all ligands evaluated showed a  $T_m$  shift of 14–27  $^{\circ}\text{C}$ , at 1  $\mu\text{M}$  ligand, for the three quadruplexes evaluated and no detectable stabilization of duplex DNA. The FRET melting data is broadly in support of the SPR measurements, although one must exercise caution in the interpretation of FRET-melting since  $T_m$  measurements relate to ligand-induced stabilization of folded structure, rather than equilibrium binding (Figure 2).

On the basis of their selectivity for c-kit2, we carried out a study on the effects of ligands **1a** and **1d** on c-kit expression. We evaluated the ligands at 5  $\mu\text{M}$  final concentration, near to the measured  $K_d$  for both compounds (Table 1). Two human cancer cell lines were used: the epithelial like breast cancer cell line MCF-7 and the gastrointestinal stromal tumor cell line HGC-27. These ligands were not toxic to either cell line at the concentration employed. Experiments were performed in MCF-7 that exhibited relatively low basal levels of c-kit expression. The ligand-induced changes in c-kit expression were measured by quantitation of mRNA using real-time polymerase chain reaction (RT-PCR) (see Supporting Information for details). These changes relative to a control gene  $\beta$ -actin are shown in Figure 3A. The results showed that after 3 h treatment with ligand **1a**, expression of c-kit was reduced by 5.4-fold and by 5-fold after 6 h (Figure 3A). For ligand **1d** expression of c-kit was reduced by 2.1-fold after 3 h and almost completely suppressed (31-fold reduction) after 6 h (Figure 3A). The strong effect of ligand **1d** prompted us to evaluate its influence on HGC-27 cells, which show much higher basal levels of c-kit oncogene expression ( $\sim$ 16-fold higher expression than MCF-7). Upon treatment with ligand **1d**, HGC-27 cells showed that c-kit gene expression was reduced by 1.8-fold, 1.9-fold, and 2.4-fold after 2, 6, and 24 h, respectively (Figure 3B). Overall, ligands show the ability to inhibit c-kit gene expression. The effect of ligand **1d** on the expression of c-kit in MCF-7 cells was much more

pronounced than in HGC-27 cells, which may be due to the different basal transcriptional levels of c-kit of these two cell lines. It was interesting to note that the inhibitory effects were observed at concentrations near the ligand  $K_d$ , which may reflect favorable cellular uptake of such compounds.

In summary, 3,8,10-trisubstituted isoalloxazines are a promising class of G-quadruplex binding ligands that show selective binding to a c-kit promoter quadruplex and have provided proof of concept for the inhibition of c-kit expression. Detailed investigations on the chemical biology of 3,8,10-trisubstituted isoalloxazines and quadruplexes are now underway.


## Acknowledgments

We thank Cancer Research U.K. for programme and project funding, the BBSRC for funding, and COMSATS University faculty development programme funding for a studentship to R.S. S.B. is a BBSRC Career Development Research Fellow. We thank Ashok Venkitaraman for valuable discussion.

## References


1. (a) Phan AT, Modi YS, Patel DJ. *J. Am. Chem. Soc.* 2004; 126:8710. [PubMed: 15250723] (b) Parkinson GN, Lee MPH, Neidle S. *Nature*. 2002; 417:876. [PubMed: 12050675]
2. Paeschke K, Simonsson T, Postberg J, Rhodes D, Lipps HJ. *Nat. Struct. Mol. Biol.* 2005; 12:847. [PubMed: 16142245]
3. (a) Huppert JH, Balasubramanian S. *Nucleic Acids Res.* 2007; 35:406. [PubMed: 17169996] (b) Todd AK, Johnston M, Neidle S. *Nucleic Acids Res.* 2005; 33:2901. [PubMed: 15914666]
4. Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH. *Proc. Natl. Acad. Sci. U.S.A.* 2002; 99:11593. [PubMed: 12195017]
5. Dai J, Chen D, Jones AR, Hurley LH, Yang D. *Nucleic Acids Res.* 2006; 34:5133. [PubMed: 16998187]
6. Sun D, Guo K, Rusche JJ, Hurley HL. *Nucleic Acids Res.* 2005; 33:6070. [PubMed: 16239639]
7. Cogoi S, Xodo LE. *Nucleic Acids Res.* 2006; 34:2536. [PubMed: 16687659]
8. (a) Fernando H, Reszka AP, Huppert J, Ladame S, Rankin S, Venkitaraman A, Neidle S, Balasubramanian S. *Biochemistry*. 2006; 45:7854. [PubMed: 16784237] (b) Rankin S, Reszka AP, Huppert J, Zloh M, Parkinson GN, Todd AK, Ladame S, Balasubramanian S, Neidle S. *J. Am. Chem. Soc.* 2005; 127:10584. [PubMed: 16045346]
9. Ou TM, Lu YJ, Huang ZS, Wang XD, Tan JH, Chen Y, Ma DL, Wong KY, Tang JC, Chan AS, Gu LQ. *J. Med. Chem.* 2007; 50:1465. [PubMed: 17346034]
10. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A. *EMBO J.* 1987; 6:3341. [PubMed: 2448137]
11. Tuveson DA, Willis NA, Jacks T, Griffin TD, Singer S, Fletcher CDM, Fletcher JA, Demetri GD. *Oncogene*. 2001; 20:5054. [PubMed: 11526490]
12. Lauhon CT, Szostak JW. *J. Am. Chem. Soc.* 1995; 117:1246. [PubMed: 11539282]
13. White EW, Taniou F, Ismail MA, Reszka AP, Neidle S, Boykin DW, Wilson DW. *Biophys. Chem.* 2007; 126:140. [PubMed: 16831507]
14. Kipnis F, Weiner N, Spoerri PE. *J. Am. Chem. Soc.* 1947; 69:799.
15. (a) Teulade-Fichou M-P, Carrasco C, Guittat L, Bailly C, Alberti P, Mergny J-L, David A, Lehn J-M, Wilson WD. *J. Am. Chem. Soc.* 2003; 125:4732. [PubMed: 12696891] (b) Schouten JA, Ladame S, Mason SJ, Cooper MA, Balasubramanian S. *J. Am. Chem. Soc.* 2003; 125:5594. [PubMed: 12733873] (c) Davis TM, Wilson DW. *Methods Enzymol.* 2001; 340:22. [PubMed: 11494851]
16. (a) Harrison RJ, Reszka AP, Haider SM, Ramagnoli B, Morell J, Read MA, Gowan SM, Incles CM, Kelland LR, Neidle S. *Bioorg. Med. Chem. Lett.* 2004; 14:5845. [PubMed: 15501053] (b) Darby RAJ, Sollogoub M, Mckeen C, Brown L, Risitano A, Brown N, Barton C, Brown T, Fox KR. *Nucleic Acids Res.* 2002; 30:e39. [PubMed: 11972354]

17. The isoalloxazines (**1a–f**) did not show any significant binding with duplex DNA at concentrations up to 200  $\mu\text{M}$ . Ligand aggregation prevented the measurement of binding at higher concentrations.
18. Hassan S, Kinoshita Y, Kawanami C, Kishi K, Matsushima Y, Ohashi A, Funasaka Y, Okada A, Maekawa T, He–Yao W, Chiba T. *Dig. Dis. Sci.* 1998; 43:8. [PubMed: 9508539]




| Ligand    | R <sub>1</sub> | R <sub>2</sub> |
|-----------|----------------|----------------|
| <b>1a</b> |                |                |
| <b>1b</b> |                |                |
| <b>1c</b> |                |                |
| <b>1d</b> |                | -F             |
| <b>1e</b> |                |                |
| <b>1f</b> |                | -OMe           |

**Figure 1.**  
Structures of isoalloxazine ligands **1a–f**.



**Figure 2.** (A) SPR binding curve for isoalloxazine **1a** to c-kit2 (●), c-kit1 (▲), and htelo (■); running buffer, 50 mM Tris-HCl pH 7.4, 100 mM KCl. (B) FRET-melting assay for c-kit1 (\*), htelo (■), c-kit2 (●), and ds DNA (▲) in the presence of **1a**; buffer, 60 mM potassium cacodylate pH 7.4.



**Figure 3.** The inhibition of c-kit gene expression by isoalloxazines. Expression of c-kit in control cells treated with 10% DMSO in water is set to 100% (black bars). Expression of c-kit in cells treated with ligands is given as a percentage of untreated controls (gray bars). For all experiments, c-kit expression has been normalized to the expression of the house-keeping gene  $\beta$ -actin: (A) levels of c-kit repression in MCF-7 cells, with indicated ligands and time points at 5  $\mu$ M final ligand concentration; (B) levels of c-kit repression in HGC-27 cells in response to ligand **1d**, after given time points at 5  $\mu$ M final concentration.

**Table 1**  
Dissociation Constants ( $K_D$ ) Measured by SPR and G-Quadruplex Stabilization ( $\Delta T_m$ ) Potential by FRET-Melting

| DNA                     | 1a   | 1b            | 1c            | 1d              | 1e            | 1f            |
|-------------------------|--|---------------|---------------|-----------------|---------------|---------------|
|                         | $K_D$ [ $\mu$ M]                           |               |               |                 |               |               |
| c-kit2                  | 3 $\pm$ 0.5                                | 5.8 $\pm$ 2.3 | 9.2 $\pm$ 1.5 | 9.7 $\pm$ 0.8   | 2.8 $\pm$ 0.5 | 7.7 $\pm$ 0.2 |
| c-kit1                  | 6.4 $\pm$ 0.1                              | 9.1 $\pm$ 2.3 | 21 $\pm$ 2    | 31 $\pm$ 1      | 4.9 $\pm$ 0.3 | 13.7 $\pm$ 1  |
| htelo                   | 43 $\pm$ 3                                 | 8.6 $\pm$ 2   | 69 $\pm$ 7    | <i>b</i>        | 21 $\pm$ 1    | 63 $\pm$ 2    |
| ds                      | nd17                                       | nd17          | nd17          | nd17            | nd17          | nd17          |
|                         | $\Delta T_m$ at 1 $\mu$ M ( $^{\circ}$ C)  |               |               |                 |               |               |
| c-kit2                  | 18   | 17.5          | 5.4           | nd <sup>a</sup> | 17.2          | 14            |
| c-kit1                  | 25.3                                       | 24.6          | 11            | nd <sup>a</sup> | 27.1          | 13.7          |
| htelo                   | 19.1                                       | 19.3          | 7             | nd <sup>a</sup> | 15.5          | 15.4          |
| ds                      | 0  | 0             | 0             | nd <sup>a</sup> | 0             | 0             |
|                         | G-Quadruplex Binding Discrimination (Fold) |               |               |                 |               |               |
| c-kit2/<br>c-kit1/htelo | 1/2/14                                     | 1/2/2         | 1/2/8         | 1/3             | 1/2/7         | 1/2/9         |

<sup>a</sup>Not determined (nd) due to intrinsic fluorescence of ligand.

<sup>b</sup>No detectable binding was observed; SPR standard deviations are given for two independent experiments;  $\Delta T_m \pm 1$   $^{\circ}$ C.